The Global Pegfilgrastim Biosimilar Market was valued at USD 2.14 Billion in 2024 and is projected to reach USD 5.83 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 12.4% during the forecast period (2024–2032). This robust growth is being driven by the increasing global incidence of cancer, the rising adoption of myelosuppressive chemotherapy, and the strong economic appeal of biosimilars as cost-effective alternatives to the reference product, Neulasta®.

As healthcare systems worldwide grapple with escalating oncology costs and strive for greater patient access, the strategic importance of Pegfilgrastim biosimilars has never been greater. These therapies play a critical role in preventing febrile neutropenia, a serious and costly complication of chemotherapy. In this blog, we profile the Top 10 Companies in the Pegfilgrastim Biosimilar Industry—a dynamic mix of global pharmaceutical giants and specialized biotech firms that are reshaping the landscape of supportive cancer care.

---

🔟 1. Novartis AG (Sandoz)

Headquarters: Basel, Switzerland
Key Offering: Ziextenzo® (LA-EP2006)

Sandoz, the biosimilars division of Novartis, is a global leader and one of the earliest and most significant players in the Pegfilgrastim biosimilar market. Ziextenzo® is approved in major markets including the European Union and the United States, where it competes directly with Neulasta®. Sandoz leverages its extensive global commercial infrastructure and deep expertise in biosimilar development to ensure broad patient access.

Strategic Initiatives:

• Extensive global commercial footprint and supply chain

• Strong focus on physician education and market access

• Commitment to expanding biosimilar portfolio in oncology and immunology

Download FREE Sample Report: Global and United States Pegfilgrastim Biosimilar Market – View in Detailed Research Report

---

9️⃣ 2. Coherus BioSciences

Headquarters: Redwood City, California, USA
Key Offering: UDENYCA® (pegfilgrastim-cbqv)

Coherus BioSciences is a pure-play oncology company that has become a major force in the U.S. Pegfilgrastim biosimilar market. UDENYCA® was one of the first biosimilars to Neulasta® approved in the United States. The company has successfully captured significant market share through aggressive pricing strategies and strategic contracting with major group purchasing organizations (GPOs).

Strategic Initiatives:

• Specialized focus on oncology biosimilars

• Innovative delivery systems, including the UDENYCA® ON-body injector

---

8️⃣ 3. Pfizer Inc.

Headquarters: New York, New York, USA
Key Offering: Nyvepria™ (pegfilgrastim-apgf)

Pfizer is a global pharmaceutical powerhouse with a substantial and growing biosimilars portfolio. The company entered the U.S. Pegfilgrastim market with Nyvepria™, leveraging its vast oncology commercial and medical affairs capabilities. Pfizer’s significant resources and established relationships with healthcare providers position it as a key competitor.

Strategic Initiatives:

• Leveraging global scale and commercial excellence

• Investment in real-world evidence generation to support product value

---

7️⃣ 4. Mylan N.V. (Viatris Inc.)

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Fulphila® (pegfilgrastim-jmdb)

Mylan, now part of Viatris, was a pioneer in the Pegfilgrastim biosimilar space. Fulphila® was the first biosimilar to Neulasta® approved by the U.S. FDA. The company, with its partner Biocon, has a strong global presence and a commitment to providing high-quality, affordable biologic medicines.

Strategic Initiatives:

• First-mover advantage in key markets like the US and Europe

• Strong partnership-based manufacturing and development model

---

6️⃣ 5. Biocon Biologics (a subsidiary of Biocon Ltd.)

Headquarters: Bangalore, India
Key Offering: Fulphila® (in partnership with Viatris)

Biocon Biologics is a leading global biosimilars company with a robust pipeline and commercial portfolio. Through its strategic partnership with Viatris, it co-developed and supplies Fulphila®. The company has a strong foothold in both developed and emerging markets, supported by its vertically integrated manufacturing capabilities.

Strategic Initiatives:

• Vertically integrated, cost-effective manufacturing

• Strategic focus on expanding access in emerging economies

Download FREE Sample Report: Global and United States Pegfilgrastim Biosimilar Market – View in Detailed Research Report

---

5️⃣ 6. Intas Pharmaceuticals Ltd.

Headquarters: Ahmedabad, India
Key Offering: Pegasta®, Pegyto (pegfilgrastim)

Intas Pharmaceuticals is a major Indian pharmaceutical company with a significant and growing international presence in the biosimilars market. Its Pegfilgrastim biosimilar is marketed under various brand names across different regions, including Europe through its partner Accord Healthcare. Intas is known for its high-quality, affordable products.

Strategic Initiatives:

• Strong presence in European and emerging markets

• Focus on building a comprehensive oncology and supportive care portfolio

---

4️⃣ 7. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, India
Key Offering: Pegfilgrastim biosimilar

Dr. Reddy’s Laboratories is a well-established Indian multinational pharmaceutical company with a strategic focus on biosimilars. The company has launched its Pegfilgrastim biosimilar in several emerging markets and is actively pursuing regulatory approvals in more stringent markets. Dr. Reddy’s leverages its strong R&D and manufacturing expertise.

Strategic Initiatives:

• Focus on regulatory approvals in key global markets

• Cost-competitive manufacturing and development

---

3️⃣ 8. Mundipharma International

Headquarters: Cambridge, United Kingdom
Key Offering: Pelgraz® (pegfilgrastim)

Mundipharma International is a global network of independent associated companies that markets Pelgraz®, its Pegfilgrastim biosimilar, in specific territories outside the United States. The company focuses on bringing specialist medicines to patients in its licensed regions, often through partnerships.

Strategic Initiatives:

• Regional focus on Europe, Latin America, and Asia-Pacific

• Partnership-driven commercial model

---

2️⃣ 9. Apollo Biosciences (Candidates for Future Entry)

Headquarters: Various
Key Offering: Pipeline Products

Beyond the currently marketed leaders, several other companies are advancing their Pegfilgrastim biosimilar candidates through clinical development and regulatory review. These include specialized biotech firms and generic pharmaceutical companies from regions like Asia and Europe, poised to enter the market and further intensify competition.

Strategic Initiatives:

• Active clinical development programs

• Focus on achieving regulatory milestones for market entry

---

1️⃣ 10. Stada Arzneimittel AG

Headquarters: Bad Vilbel, Germany
Key Offering: Grastofil® (pegfilgrastim) in specific regions

STADA is a European pharmaceutical company with a strong generics and biosimilars business. It markets its Pegfilgrastim biosimilar, often under the brand name Grastofil®, in various countries, primarily within Europe and other international markets. STADA’s strategy focuses on providing high-quality specialty medicines.

Strategic Initiatives:

• Strong regional footprint in Europe

• Strategic acquisitions to bolster biosimilar portfolio

Get Full Report Here: Global and United States Pegfilgrastim Biosimilar Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Pegfilgrastim Biosimilars is Competitive and Patient-Centric

The Pegfilgrastim biosimilar market is undergoing a significant transformation. While the reference product still holds a portion of the market, competition from biosimilars is intensifying, leading to substantial cost savings for healthcare systems and improved patient access. The industry is evolving beyond simple price competition to focus on value-added services, innovative delivery devices, and robust real-world evidence.

📈 Key Trends Shaping the Market:

• Accelerating biosimilar adoption driven by healthcare cost containment pressures

• Innovation in drug delivery systems, such as on-body injectors for patient convenience

• Expansion into emerging markets with growing cancer care infrastructure

• Strategic consolidation and partnerships to enhance global reach and pipeline strength

Get Full Report Here: Global and United States Pegfilgrastim Biosimilar Market – View in Detailed Research Report

The companies listed above are not only providing essential supportive care for cancer patients—they are driving the sustainable and affordable future of global oncology treatment.